Filing Flows › 8-K events › Entera Bio
Entera Bio: results of operations
Form 8-K filed Nov 6, 2026 · items 2.02, 7.01
FDA decisionsEntera Announces Third Quarter 2026 Financial Results and Business Updates
What the filing says
Entera Announces Third Quarter 2026 Financial Results and Business Updates Clinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026
Read the filing on SEC EDGAR →
What usually followsAcross 69,115 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →
Entera Bio at a glance
Entera Bio, Q1 2025: revenue $42K. The chart follows the revenue to costs, profit and cash.
Entera Bio: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
- Schrodinger Nov 4, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.